论文部分内容阅读
目的 研究Smad7、TGFβRⅠ蛋白在肝细胞癌 (hepatocellularcarcinoma ,HCC)中的表达及与其临床病理的关系 ,探讨Smad7在HCC发生、发展中的作用。方法 应用SP免疫组化染色法 ,检测 62例HCC中Smad7、TGFβRⅠ蛋白表达情况 ,并分析它们与HCC临床病理的关系。 结果 62例HCC组织中Smad7、TGFβRⅠ蛋白的阳性表达率分别为 85 .48%、2 9.0 3 % ,Smad7表达明显高于正常肝组织 ,而TGFβRⅠ表达明显低于正常肝组织 (P <0 .0 5 ) ,两者在HCC中表达呈负性相关。且Smad7蛋白表达与肿瘤的临床分期及有无瘤栓、包膜完整性、复发时间长短、血AFP、肿瘤结节数及有无转移有相关性。结论 Smad7与HCC发生、发展密切相关。
Objective To investigate the expression of Smad7 and TGFβRI in hepatocellular carcinoma (HCC) and its relationship with clinicopathological features and to explore the role of Smad7 in the development and progression of HCC. Methods SP immunohistochemical staining was used to detect the expression of Smad7 and TGFβRI in 62 cases of HCC, and to analyze their relationship with clinicopathological features of HCC. Results The positive rates of Smad7 and TGFβRI in 62 HCC tissues were 85.4% and 29.03% respectively, the expression of Smad7 was significantly higher than that in normal liver tissue, whereas the expression of TGFβRⅠ was significantly lower than that in normal liver tissue (P <0. 0 5), the two were negatively correlated in HCC expression. The expression of Smad7 was correlated with clinical stage, tumor-free suppository, capsule integrity, length of recurrence, blood AFP, tumor nodules and metastasis. Conclusion Smad7 is closely related to the occurrence and development of HCC.